Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2020

View Archived Issues

Initial phase I data presented for BFCR-4350A in relapsed/refractory multiple myeloma

Mouse model of malformations of cortical development and epilepsy

Positive topline data from pivotal phase III study of setmelanotide in BBS and Alstrom syndrome

Phase III DOM-INNATE trial of SGX-942 does not show statistically significant benefit

FDA approves Ebanga for the treatment of Zaire ebolavirus

Ultimovacs initiates phase II FOCUS study of its universal cancer vaccine in head and neck cancer

Emory University patents legumain inhibitors

IFM Due discloses hSTING receptor antagonists

Inflammatory protein can distinguish between good and bad microbes

Merck & Co. identifies new coagulation factor XIa inhibitors

Genentech and Roche present new bacterial SpsB and/or LepB inhibitors

Ultragenyx Pharmaceutical discovers new HFE-expressing polynucleotides

Cord blood-derived Treg product CK-0801 safe and beneficial in clinical trial

GBT-021601 improves the pathophysiology of sickle cell disease in vivo

FDA accepts IND for CERC-007 for Still's disease

FDA places clinical hold on RESTORE-1 trial of NBIb-1817

PKLR activator mitapivat shows promising preclinical data in murine hereditary spherocytosis

Disease-modifying anle-138b enters phase Ib study in patients with Parkinson's disease

New humanized graft-versus-host disease mouse model supports NK cell engraftment

FDA approves Kineret to treat deficiency of IL-1 receptor antagonist

Phase III study of SPN-812 for adult ADHD meets primary endpoint

SOURCE trial of tezepelumab in severe asthma misses primary endpoint

FDA places clinical hold on uniQure's hemophilia B gene therapy program

BioCryst reports part 1 data from clinical trial of galidesivir in COVID-19

Acticor initiates phase II trial of glenzocimab to treat COVID-19 related ARDS